Odatroltide

【2024年9月25日，台北訊】晟德大藥廠（以下簡稱晟德，代號：4123.TW）今（25）日董事會通過認購順天醫藥生技股份有限公司（以下簡稱順藥，代號：6535TW）現金增資案，認購價格為每股新台幣225元，依照原持股比例認購1,049,259股，約合新台幣2.36億元。此外，晟德看好順藥在中風新藥領域的發展前景，擬進一步加碼投資，總金額上看4億元。 順藥於本月4日決議辦理113年現金增資，發行普通股4,000千股，總募集金額達新台幣9億元。作為順藥的第一大股東，晟德認為順藥目前正處於中風新藥LT3001解盲前的關鍵時刻，該新藥若成功解盲，將為全球中風治療領域帶來革命性突破。為全力支持順藥順利完成此次增資，晟德董事會決議加碼投資，將持股比例提升至最高33.05%。

(May 14, 2024, Taipei) Lumosa Therapeutics Co., Ltd. (Lumosa; code:6535.TWO) today held an institutional investors' conference and announced the Board's resolutions for a new equity financing round and key management changes. Ms. Su-Chi Wang, the representative nominated by Lumosa's largest shareholder Center Laboratories Group, has been appointed as the new Chairman of the Board. Dr. Sheng-Wen Yeh from the Preclinical Development Division will assume the role of General Manager, while the former Chairman and General Manager Mr. Rong-Jin Lin is stepping down temporarily to focus on strategic initiatives. As Lumosa's lead stroke therapy LT3001 approaches a critical juncture for global licensing, Mr. Lin will leverage his expansive network across Center Laboratories Group's international pharmaceutical investment portfolio to maximize LT3001's worldwide commercialization prospects. The new General Manager Dr. Sheng-Wen Yeh has been the driving force behind LT3001's development from compound selection, preclinical validation, mechanism elucidation to clinical trial design over the past decade. She will apply her product expertise to execute a de-risked clinical strategy and ensure the pivotal studies achieve their endpoints. With the Group's licensing capabilities, Lumosa aims to unlock LT3001's full value proposition. "Establishing a top 50 global pharmaceutical company from Taiwan has been my lifelong mission," said Mr. Lin. "Now that LT3001 has reached an important inflection point, I will marshal the Group's resources to clear the path for its global licensing. Dr. Yeh is undoubtedly the world's foremost scientific authority on LT3001 and the ideal person to lead Lumosa. I look forward to our licensingt and clinical initiatives converging to complete LT3001's final step onto the world stage." In today's institutional investors' conference, Dr. Sheng-Wen Yeh provided updates on the key pipeline programs: For the three pivotal Phase 2 studies of LT3001 underway, patient enrollment in the China study conducted by regional partner Shanghai Pharmaceutical Holdings has exceeded expectations, with over 80% of the target number of patients already enrolled. Last Patient In (LPI) is expected in mid-2024, keeping the study on track for data readout by year-end. The two global studies led by Lumosa are projected to complete in 2025. In parallel, Lumosa is actively investing in next-generation modalities beyond LT3001, spanning exosome and allogeneic cell therapies. The Company recently invested in the innovative gene editing firm GenEditBio to enter the gene therapy space, exploring various emerging therapeutic platforms. Lumosa's marketed long-acting analgesic LT1001 has obtained marketing approvals across six countries to date and will continue to pursue niche market opportunities to provide financial optionality. Looking ahead, successful LT3001 commercialization is expected to fuel the incubation of Lumosa's future innovative pipeline and reinforce its sustainable business model.